Androgenic pathways in the progression of triple-negative breast carcinoma: A comparison between aggressive and non-aggressive subtypes

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 281-293

  McNamara, Keely M ^a   Yoda, Tomomi ^a   Nurani, Alif Meem ^a   Shibahara, Yukiko ^a   Miki, Yasuhiro ^a   Wang, Lin ^b   Nakamura, Yasuhiro ^a   Suzuki, Koyu ^c   Yang, Yang ^a,c   Abe, Eriko ^a,c   Hirakawa, Hisashi ^d   Suzuki, Takashi ^a   Nemoto, Noriko ^a   Miyashita, Minoru ^a   Tamaki, Kentaro ^a,e   Ishida, Takanori ^a   Brown, Kristy A ^f   Ohuchi, Noriaki ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Physiology Harbin Medical University Daqing Branch   (China)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^d TOHOKU ROSAI HOSPITAL   (Japan)

^e Nahanishi Clinic   (Japan)

^f HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Androgen receptor; Basal type breast cancer; DCIS; IDC; Steroid metabolism; Triple negative breast cancer

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; MESSENGER RNA; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN; ANDROGEN; ANDROSTANOLONE; AR PROTEIN, HUMAN; CHOLESTENONE 5ALPHA REDUCTASE; CYTOKERATIN 5; CYTOKERATIN 6; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFORMED CONSENT; INTRADUCTAL CARCINOMA; JAPAN; MICROARRAY ANALYSIS; PREVALENCE; PRIORITY JOURNAL; THAILAND; TRIPLE NEGATIVE BREAST CANCER; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

3-HYDROXYSTEROID DEHYDROGENASES; ANDROGENS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLESTENONE 5 ALPHA-REDUCTASE; DIHYDROTESTOSTERONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; KERATIN-5; KERATIN-6; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84901688873     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2942-6     Document Type: Article

References (40)

1. Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36(3):206-215. doi: 10.1016/j.ctrv.2009.12.002
2. Hickey TE, Robinson JL, Carroll JS, Tilley WD (2012) Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 26(8):1252-1267. doi: 10.1210/me.2012-1107
3. McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H (2013) Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 133:66-76. doi: 10.1016/j.jsbmb.2012.08.007
4. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24(29):4660-4671. doi: 10.1038/sj.onc.1208561 (Pubitemid 41032603)
5. Ormandy CJ, Clarke CL, Kelly PA, Sutherland RL (1992) Androgen regulation of prolactin-receptor gene expression in MCF-7 and MDA-MB-453 human breast cancer cells. Int J Cancer 50(5):777-782
6. Hall RE, Tilley WD, McPhaul MJ, Sutherland RL (1992) Regulation of androgen receptor gene expression by steroids and retinoic acid in human breast-cancer cells. Int J Cancer 52(5):778-784
7. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD (1995) Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 52(5):459-467
8. Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD (1999) Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol 154(1-2):11-20 (Pubitemid 29387325)
9. Mitchell S, Abel P, Madaan S, Jeffs J, Chaudhary K, Stamp G, Lalani el N (2002) Androgen-dependent regulation of human MUC1 mucin expression. Neoplasia 4(1):9-18 (Pubitemid 34075886)
10. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25(28):3994-4008. doi: 10.1038/sj.onc.1209415 (Pubitemid 43990755)
11. Robinson JL, MacArthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, Carroll JS (2011) Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J 30(15):3019-3027. doi: 10.1038/emboj.2011.216
12. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, Henshall SM, Birrell SN, Coetzee GA, Sutherland RL, Butler LM, Tilley WD (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69(15):6131-6140. doi: 10.1158/0008-5472.CAN-09-0452
13. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750-2767. doi: 10.1172/JCI45014
14. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M (2011) Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20(1):119-131. doi: 10.1016/j.ccr.2011.05.026
15. McNamara K, Yoda T, Miki Y, Chanplakorn N, Wongwaisayawan S, Incharoen P, Kongdan Y, Wang L, Takagi K, Mayu T, Nakamura Y, Suzuki T, Nemoto N, Miyashita M, Tamaki K, Ishida T, Ohuchi N, Sasano H (2013) Androgenic pathway in triple negative invasive ductal tumours: its correlation with tumour cell proliferation. Cancer Sci 104(5):639-646. doi: 10.1111/cas.12121
16. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120(5):725-731. doi: 10.1309/42F0-0D0D-JD0J-5EDT (Pubitemid 37339680)
17. Luo X, Shi YX, Li ZM, Jiang WQ (2010) Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer 29(6):585-590
18. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25-32. doi: 10.1002/cncr.22381 (Pubitemid 46120191)
19. Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, Pelletier G (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24(2):152-182 (Pubitemid 36515283)
20. Allred DC (2010) Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr 2010(41):134-138. doi: 10.1093/jncimonographs/lgq035
21. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684-1691. doi: 10.1200/JCO.2009.24.9284
22. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368-1376. doi: 10.1158/1078-0432.ccr-07-1658 (Pubitemid 351413917)
23. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28(20):3271-3277. doi: 10.1200/JCO.2009.25.9820
24. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J (2011) Androgen regulation of 5alpha-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One 6(12):e28840. doi: 10.1371/journal.pone.0028840
25. Schulze JJ, Karypidis H, Ekstrom L (2012) Basal and regulatory promoter studies of the AKR1C3 gene in relation to prostate cancer. Front Pharmacol 3:151. doi: 10.3389/fphar.2012.00151
26. Asjoe FT, Altintas S, Huizing MT, Colpaert C, Marck EV, Vermorken JB, Tjalma WA (2007) The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: A retrospective analysis. Breast J 13(4):359-367. doi: 10.1111/j.1524-4741.2007.00443.x (Pubitemid 46985562)
27. Tamaki K, Ishida T, Tamaki N, Kamada Y, Uehara K, Miyashita M, Amari M, Tadano-Sato A, Takahashi Y, Watanabe M, McNamara K, Ohuchi N, Sasano H (2012) Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients. Breast Cancer. doi: 10.1007/s12282-012-0387-5
28. Miyashita M, Ishida T, Ishida K, Tamaki K, Amari M, Watanabe M, Ohuchi N, Sasano H (2011) Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates. Virchows Arch 458(1):65-72. doi: 10.1007/s00428-010-1009-2
29. Coletta A, Molter C, Duque R, Steenhoff D, Taminau J, de Schaetzen V, Meganck S, Lazar C, Venet D, Detours V, Nowe A, Bersini H, Weiss Solis DY (2012) InSilico DB genomic datasets hub: An efficient starting point for analyzing genome-wide studies in GenePattern, Integrative Genomics Viewer, and R/Bioconductor. Genome Biol 13(11):R104. doi: 10.1186/gb-2012-13-11-r104
30. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP (2006) GenePattern 2.0. Nat Genet 38(5):500-501. doi: 10.1038/ng0506-500
31. Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA (2012) TNBCtype: A subtyping tool for triple-negative breast cancer. Cancer Inform 11:147-156. doi: 10.4137/CIN.S9983
32. Thike AA, Iqbal J, Cheok PY, Tse GM, Tan PH (2013) Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship. J Clin Pathol. doi: 10.1136/jclinpath-2012- 201428
33. Ishikawa Y, Horiguchi J, Toya H, Nakajima H, Hayashi M, Tagaya N, Takeyoshi I, Oyama T (2011) Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological features. Cancer Sci 102(3):656-662. doi: 10.1111/j.1349-7006.2011.01858.x
34. Aguiar FN, Mendes HN, Bacchi CE, Carvalho FM (2013) Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast. Rev Bras Ginecol Obstet 35(3):97-102
35. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. Br J Cancer 96(10):1504-1513. doi: 10.1038/sj.bjc.6603756 (Pubitemid 46762956)
36. Shibuya R, Suzuki T, Miki Y, Yoshida K, Moriya T, Ono K, Akahira J, Ishida T, Hirakawa H, Evans DB, Sasano H (2008) Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr Relat Cancer 15(1):113-124. doi: 10.1677/ERC-07-0092 (Pubitemid 351449732)
37. Ni M, Chen Y, Fei T, Li D, Lim E, Liu XS, Brown M (2013) Amplitude modulation of androgen signaling by c-MYC. Genes Dev 27(7):734-748. doi: 10.1101/gad.209569.112
38. Hackenberg R, Luttchens S, Hofmann J, Kunzmann R, Holzel F, Schulz KD (1991) Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Res 51(20):5722-5727
39. Yeap BB, Krueger RG, Leedman PJ (1999) Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology 140(7):3282-3291 (Pubitemid 30650647)
40. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA, Translational Breast Cancer Research Consortium (2013) Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res 19(19):5505-5512. doi: 10.1158/1078-0432.CCR-12-3327